Head-to-head evidence
Aripiprazole (Abilify Maintena) vs Brexpiprazole (Rexulti)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2/D3 and serotonin 5-HT1A receptor · full Schizophrenia pipeline
Aripiprazole (Abilify Maintena)
Marketed by Otsuka Holdings and partners
NCT00706654 · Phase 3 · completed
This was a randomized, double-blind, active-controlled trial with 662 randomized maintenance-phase participants, including 265 assigned to depot 300/400 mg and 266 to oral aripiprazole. The primary clinical relapse endpoint was met: depot treatment was non-inferior to oral aripiprazole, with a difference of -0.64 percentage points and a 95% confidence interval of -5.26 to 3.99, below the prespecified 11.5% margin.
Next expected readout: December 2027 · NCT07047651 (registry estimate)
Brexpiprazole (Rexulti)
Marketed by Otsuka Holdings and partners
NCT01393613 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial in 674 patients with acute schizophrenia, using a validated symptom-severity scale (PANSS) as the primary measure. The pooled comparison of the two higher doses against placebo reached statistical significance (p=0.0093), and the 4 mg dose was significant on its own, but the 1 mg and 2 mg doses individually did not separate from placebo, so the result was only partially met.
Next expected readout: August 2027 · NCT07742280 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aripiprazole (Abilify Maintena)'s landscape · Brexpiprazole (Rexulti)'s landscape